Lymphoma, Large B-Cell, Diffuse
Conditions
Keywords
Positron-Emission Tomography, Prognosis
Brief summary
The purpose of this study is to evaluate whether a semi-quantitative interpretation using the liver SUVmax as reference can better interpret 18F-FDG PET/CT and predict disease progression during chemotherapy or survival in DLBCL.
Detailed description
In this study investigators develope a semi-quantitative interpretation using the liver SUVmax as reference to interpret 18F-FDG PET/CT. Positive lesions in PET were indicated as SUVmax of residues higher than the threshold (1.6 fold of liver SUVmax) or new 18F-FDG avid lesions. Investigators compare the prognostic accuracy of the liver SUVmax-based criteria with the 5-PS criteria and ΔSUVmax interpretation with respect to predicting disease progression during chemotherapy or survival in DLBCL. Furthermore,investigators improve the prognostic ability of interim PET/CT by comparing the results to the clinical prognostic factors.
Interventions
DEVICE18F-FDG PET/CT
18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post-injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
Sponsors
Peking University Cancer Hospital & Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* newly diagnosed DLBCL * treated using an anthracycline-containing regimen with or without rituximab * minimal follow-up at 6 months after the completion of first-line treatment * complete medical history and clinicopathological data
Exclusion criteria
* secondary malignant disease * serious infection or inflammation (e.g., HIV) * primary central nervous system lymphoma * hepatic or renal dysfunction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in summed standardized uptake value (SUVmax) of lesion after 2 or 4 cycles | baseline(diagnosed by pathology and before chemotherapy) and 2 or 4 cycles after starting chemotherapy (each cycle 21days) |
Secondary
| Measure | Time frame |
|---|---|
| 2 year progression-free survival | up to 2 years after initial diagnosis |
Countries
China
Contacts
Primary ContactXuejuan Wang, MD
Outcome results
None listed